A Team-Based Approach to Clinical Trial Accrual

Speakers

Greg Nowakowski, MD
Consultant
Mayo Clinic

Leslie Hampson-Yazdi, AIA, NCARB, LEED AP
Founding member, OPACT Group
New F. Graham Cancer Center & Research Institute,
Christiana Care Health System

Karen Poe, RN, BS, OCN
Manager of Clinical Research
Texas Oncology Tyler

Jasmine Kamboj, MD, MBBS
Hematologic Oncologist
Allina Health

Leila Hamroun-Yazid, AIA, NCARB, LEED AP
Founding member, OPACT Group
New F. Graham Cancer Center & Research Institute,
Christiana Care Health System

Clincial Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic

Clinical Trial – A Standard Therapy in 2019

Greg Nowakowski
Mayo Clinic
Yet, Only 5 to 7% of US Patients Benefit by Entering Clinical Trials

1.7 million patients diagnosed with cancer in US in 2019

No clinical trial available (anywhere)
5% of patients on CT
Not meeting criteria
Yes, there is a trial somewhere and you eligible

1.7 million patients diagnosed with cancer in US in 2019

Local access
Patient perception
Socio-economic factors
Patients' hunger for CT

0/20 people pic
0/20 name

0/20 people pic
0/20 name

3/20 name

0/20 people pic
0/20 name

0/20 people pic
0/20 name

0/20 people pic
0/20 name
Who is that?

Based on random sample of 20 US patients in my clinic.

How Do We Make People “Hungry” for Clinical Trials?

- Education about CT
  Types and scientific question
  Role in drug approval
  Potential for personal benefit
  “this is to help you”
- PR Campaign
  Partnership with industry and government agencies
  Patients stories
- Stories about Cancer Care giants
  The message: “if you not on the trial you are not on the right treatment”

I want these 3 to match up to Mike or Kim….

“Trust us” .... Why should I?
A Patient’s Perspective

Leila Hamroun, AIA, NCARB, LEED AP
Oncology Patient Advocates for Clinical Trials (OPACT)
Christiana Health Care System

In Theory….

In Practice….
In Practice….

Actual quotes heard this week

- I hear the chemotherapy is worse than the disease.
- TV personality X said that it was a real nightmare.
- Remember the movies on Tuskegee and Henrietta Lacks?
- Homeopathic remedies are really about me, not a drug company.

“Restoring” Trust?

- Not sure trust ever really was there.
- To create trust we need to:
  - Listen
  - Educate
  - Convince
  - Above all… Be humble.

Words Matter

**ACCURAL**

*Definition in the Cambridge English Dictionary*

- Accurate
- Accurate

**Actions Matter**

Universal and Uniform Access

Access for Underserved Populations

Jasmine Kamboj, MD, MBBS

Aliina Health
Access to Clinical Trials
- Hub-and-spoke model
- Telemedicine
- Eligibility criteria
- Communication, collaboration, capacity building

Provider Education and Resources
- Project ECHO
- Education of Research team
- Burn out and isolation
- Reimbursement

Patient Resources and Advocacy
- The 3As
- Representation from minority populations
- Targeted outreach

And the one last thing...

Site Engagement
Karen Poe, RN, BSN, OCN
Texas Oncology-Tyler
Physician Engagement as an Effective Accrual Strategy

Secret Sauce? Magic Bullet?

2.9 patients = Average yearly accrual per investigator to oncology clinical trials
4.8 patients = Average yearly for US Oncology network investigator (2017-18)
32.5 patients = Average yearly accrual for Texas Oncology Tyler investigator (2017-18)


US Oncology Research, Clinical Trials Management System, 2017, 2018, 2019

Commitment to Research = Physician Engagement

Factors affecting physician engagement in clinical trials:
- Extra/extended clinic visits
- Extra time for patients/education
- Extra paperwork

Barriers to Physician Engagement

| Time | Time-consuming paperwork | Time needed for patient and self education on trial specifics | Time required to perform extra visits, specific trial procedures and extended follow up schedule |

Optimize Physician Engagement

- Streamline processes
  - Integrated computer applications
  - Network infrastructure
  - Research dedicated staff
- Culturalization
  - Physician Orientation
  - Disease committee participation
  - Healthy Competition
  - Fine-tuned research SOPs
  - Setting expectations

Make it Easy! Be a Research Optimized Site

- Maximize Resources
  - Research dedicated professionals
  - Advanced Practice Providers
  - Pre-identification/screening
  - Trial awareness/notification system
  - Coordination of care
  - Easy Access to resources (staff, information)

Discussion

Leslie Byatt, CPHT, CCRC
New Mexico Cancer Care Alliance
What Has Worked: Patient Perspective

What Has Worked: Rural Barriers

What Has Worked: Physician Engagement

What Has Worked: Clinical Trial Access

Thank you!